SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in 60 Degrees Pharmaceuticals

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a shared beneficial ownership of 476,866 shares, representing 9.99% of 60 Degrees Pharmaceuticals, Inc.'s common stock as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in 60 DEGREES PHARMACEUTICALS, INC.
• The filing indicates that as of December 31, 2024, the Reporting Persons collectively beneficially own 476,866 shares of Common Stock, par value $0.0001, of 60 Degrees Pharmaceuticals, Inc.
• This aggregate amount represents 9.99% of the issuer's class of securities.
• The Reporting Persons hold shared voting power and shared dispositive power over all 476,866 shares.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: This filing is a standard disclosure of beneficial ownership and does not contain performance or strategic updates that would indicate a positive or negative sentiment.

Future Outlook

This document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding the issuer's future performance or outlook.

Management Comments

• The Reporting Persons certify that, to the best of their knowledge and belief, the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This Schedule 13G filing is a standard regulatory disclosure of a significant ownership stake by an institutional investor and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and potentially share price.

Key Dates

Keywords

60 Degrees Pharmaceuticals, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing